Evidence map›Paper›PMID 37184206›Full record

ArticlemAbs

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.

Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, Nicolas Bouquin, Stéphanie Cornen, Francis Duffieux, Pierre Ferré, Raphaëlle Gillet, Christian Jorgensen, Mark B Leick and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Ana AntunesMabDesign, Lyon, France.
Luis Alvarez-VallinaCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Federico BertoglioTechnische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address.
Nicolas BouquinREGIMBEAU, Paris - 69006 Lyon, France.
Stéphanie CornenInnate Pharma, Marseille, France.
Francis DuffieuxLarge Molecules Research, Sanofi, Vitry-Sur-Seine, France.
Pierre FerréCompugen Ltd, Holon, Israel.
Raphaëlle GilletREGIMBEAU, Paris - 69006 Lyon, France.
Christian JorgensenIRMB, université de Montpellier, Inserm U1183, Montpellier, France.
Mark B LeickCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Bernard MaillèreUniversité de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
Hélène NegreInstitut de Recherches Internationales Servier, Suresnes, France.
Mireia PelegrinIRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France.
Nicolas PoirierOSE Immunotherapeutics, Nantes, France.
Dietmar ReuschPharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany.
Bruno RobertIRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.ORCID 0000-0001-5573-6945
Guy SerreInstitut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France.
Alain VicariCalypso Biotech SA, Plan-les-Ouates, Switzerland.
Martin VillalbaIRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France.
Christoph VolpersMichalski Huettermann & Partner, Frankfurt/Main, Germany.
Gavin VuddamalayMabDesign, Lyon, France.
Hervé WatierCEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France.
Thierry WurchEvotec, Toulouse, France.
Lennart ZabeauOrionis Biosciences BV, Ghent, Belgium.
Stefan ZielonkaProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Baolin ZhangOffice of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Alain BeckBiologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France.ORCID 0000-0002-4725-1777
Pierre MartineauIRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.ORCID 0000-0002-7993-7183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The annual "Antibody Industrial Symposium", co-organized by LabEx MAbImprove and MabDesign, held its 10th anniversary edition in Montpellier, France, on June 28-29, 2022. The meeting focused on new results and concepts in antibody engineering (naked, mono- or multi-specific, conjugated to drugs or radioelements) and also on new cell-based therapies, such as chimeric antigenic receptor (CAR)-T cells. The symposium, which brought together scientists from academia and industry, also addressed issues concerning the production of these molecules and cells, and the necessary steps to ensure a strong intellectual property protection of these new molecules and approaches. These two days of exchanges allowed a rich discussion among the various actors in the field of therapeutic antibodies.

Indexed as

Antibodies, MonoclonalImmunotherapy, AdoptiveFranceAntibodies, MonoclonalAntibody engineeringAntibody industrial symposiumantibody-related moleculesbiotherapeuticscell-based therapiescongressIntellectual propertyresearch translation into clinictherapeutic antibodies

Identifiers

PMID37184206
PMCPMC10187075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.